These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10815092)

  • 1. Ancrod--is snake venom an antidote for stroke?
    Mayberg MR; Furlan A
    JAMA; 2000 May; 283(18):2440-2. PubMed ID: 10815092
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin in acute ischemic stroke.
    Longstreth WT
    JAMA; 2000 Sep; 284(11):1379. PubMed ID: 10989387
    [No Abstract]   [Full Text] [Related]  

  • 3. Ancrod.
    Sherman DG
    Curr Med Res Opin; 2002; 18 Suppl 2():s48-52. PubMed ID: 12365829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with Ancrod in acute ischaemic stroke.
    Nuber R
    Cerebrovasc Dis; 2000; 10 Suppl 4():27-9. PubMed ID: 11070397
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimal timing of thrombolytic therapy in acute ischaemic stroke.
    Madden K
    CNS Drugs; 2002; 16(4):213-8. PubMed ID: 11945105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
    Sherman DG; Atkinson RP; Chippendale T; Levin KA; Ng K; Futrell N; Hsu CY; Levy DE
    JAMA; 2000 May; 283(18):2395-403. PubMed ID: 10815082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation.
    Spiess BD; Gernsheimer T; Vocelka C; Chandler WL; Benak A; Joy JV; Wright I; Hofer BO
    J Cardiothorac Vasc Anesth; 1996 Dec; 10(7):918-21. PubMed ID: 8969402
    [No Abstract]   [Full Text] [Related]  

  • 8. [The evaluation of thrombolytic effect of snake venom antithrombus enzyme in treatment of acute myocardial infarction].
    Zhang SY; Jin L; Yan XW
    Zhonghua Nei Ke Za Zhi; 1994 Apr; 33(4):244-7. PubMed ID: 7956563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ancrod in the treatment of acute ischaemic stroke.
    Atkinson RP
    Drugs; 1997; 54 Suppl 3():100-8. PubMed ID: 9360857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.
    Hennerici MG; Kay R; Bogousslavsky J; Lenzi GL; Verstraete M; Orgogozo JM;
    Lancet; 2006 Nov; 368(9550):1871-8. PubMed ID: 17126719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of acute ischemic stroke].
    Minematsu K
    No To Shinkei; 2004 Nov; 56(11):921-6. PubMed ID: 15678948
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents.
    Clark WM; Lutsep HL
    Neuroimaging Clin N Am; 1999 Aug; 9(3):465-73. PubMed ID: 10433639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator approved for stroke.
    Barber A; Gommans J
    N Z Med J; 2005 May; 118(1214):U1432. PubMed ID: 15886728
    [No Abstract]   [Full Text] [Related]  

  • 14. Ancrod and fibrin formation: perspectives on mechanisms of action.
    Liu S; Marder VJ; Levy DE; Wang SJ; Yang F; Paganini-Hill A; Fisher MJ
    Stroke; 2011 Nov; 42(11):3277-80. PubMed ID: 21868728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of tissue plasminogen activator to treat acute ischemic stroke.
    Alexandrov AW
    Crit Care Nurse; 2010 Oct; 30(5):77-8. PubMed ID: 20889516
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT).
    Samsa GP; Matchar DB; Williams GR; Levy DE
    J Eval Clin Pract; 2002 Feb; 8(1):61-70. PubMed ID: 11882102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hope on the horizon for stroke patients.
    Cornell DH
    N J Med; 1998 Apr; 95(4):61-3. PubMed ID: 16010797
    [No Abstract]   [Full Text] [Related]  

  • 18. Can the therapeutic window for tissue plasminogen activator be extended to 6 hours after stroke onset?
    Alexandrov AV
    Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):342-3. PubMed ID: 16265558
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department.
    ; Brown MD; Burton JH; Nazarian DJ; Promes SB
    Ann Emerg Med; 2015 Sep; 66(3):322-333.e31. PubMed ID: 26304253
    [No Abstract]   [Full Text] [Related]  

  • 20. Can quality-adjusted life-years and subgroups help us decide whether to treat late-arriving stroke patients with tissue plasminogen activator?
    Waxman DA; Keeler E
    Ann Emerg Med; 2013 Jan; 61(1):56-7. PubMed ID: 22841181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.